From: Bruce Moskowitz -4

From: Bruce Moskowitz -4 To: Ellen Marmur Cc: Colleen Obrien r>, Renee O'Brien , Karyna Shuliak Subject: Re: Karyna Date: Tue, 11 Dec 2018 19:28:52 +0000 No I only did her lab so indeed I can not tell you any more since I did not do a full exam. I would recommend a different medication without side effect profile and a full exam both from internal medicine and gynecology in view of the medication regimen. Sent from my iPad Bruce Moskowitz M.D. On Dec 11, 2018, at 2:24 PM, Ellen Marmur > wrote: Dear Dr. Moskowitz, Thank you for your email. To clarify and for medicolegal purposes, you are her internist and have examined Ms. Shuliak and are confirming that she is currently in good health with respect to her levels of cholesterol, LFTs, and triglycerides. Please confirm yes. You will continue to see her in person and monitor her labs monthly with us in collaboration while she is on Claravis 20 mg. Please confirm yes. Sincerely, Dr Marmur On Tue, Dec 11, 2018 at 2:00 PM Bruce Moskowitz cl > wrote: We will continue to monitor cholesterol if increases will need to choose another option for therapy I would recommend recheck in two weeks. Thank you Sent from my iPad Bruce Moskowitz M.D. Dr. Ellen Marmur President/Founder, Marmur Medical 12 East 87th Street, Suite IA NY NY 10128 Associate Clinical Professor, The Department of Dermatology Associate Clinical Professor, The Department of Genomics & Genetic Science The Mount Sinai Medical Center New York, New York 10029 •SECURITY/CONFIDENTIALITY WARNING: This message and any attachments are intended solely for the individual or entity to which they are addressed. This communication may contain information that is privileged, confidential, or exempt from disclosure under applicable law (e.g., personal health information, research data, financial information). Because this e-mail has been sent without encryption, individuals other than the intended recipient EFTA00550989 may be able to view the information, forward it to others or tamper with the information without the knowledge or consent of the sender. If you are not the intended recipient, any dissemination, distribution or copying of the communication is strictly prohibited. If you received the communication in error, please notify the sender immediately by replying to this message and deleting the message and any accompanying files from your system. If, due to the security risks, you do not wish to receive further communications via e-mail, please reply to this message and inform the sender that you do not wish to receive further e-mail from the sender. EFTA00550990